• CAR-iNK & CAR-iT Assay Development
    • in Vivo & In Vitro Assays
    • Optimized Protocols for a Fast Turnaround
    CAR-iNK & CAR-iT Assay Development

iPSC based CAR-NK & CAR-T Assay Services

As gene editing technologies evolve, the number of potential engineered cell-based treatments continues to increase. With tools such as CRISPR and TARGATTTM, it is easier than ever before to insert chimeric antigen receptor (CAR) genes into iPSCs that can be further differentiated into natural killer (NK) or T cells. While there is still plenty of cancer immunotherapy research to be done, CAR-iNK and CAR-iT cell engineering provides a great opportunity for the development of therapeutics that could potentially target and eliminate various forms of cancer. These new cell therapies could be revolutionary, but before entering clinical trials, it is important to ensure these candidates are effective and safe.

Whether you are looking to start your in vitro experiments or in vivo preclinical studies, Applied StemCell can help you design the right efficacy, safety, or toxicity assay for your cancer immunotherapy research. ASC offers a series of customizable iPSC-based CAR-NK and CAR-T cell assay services. Our team has several years of experience working with iPSCs and iPSC-derived products, so we guarantee we can create assays that capture all your requirements and deliver detailed intermediate and final reports with essential quantitative data for your preclinical studies.

  • Fully Customizable
  • In vivo and in vitro efficacy, safety, and toxicity preclinical studies
  • In vitro Assays: humanized mouse models engineered in the U.S.A.
  • Fast & Affordable

As a leading iPSC CRO/CDMO, we also offer iPSC differentiation services to NK and T cells from your healthy/disease iPSCs or our well-characterized control lines. Our experts can even use our proprietary knock-in technology, TARGATT™ to integrate your CAR gene(s) onto your iPSCs prior to the differentiation process. Additionally, we can assist in the optimization of your CAR design to increase expression. If you would like to learn more, contact us today or visit our TARGATT™ iPSC-iNK Platform page for more details.


In Vitro Assays

Available Assays

Phenotyping Assays - For markers CD45 & CD56

(Post CAR-iPSC Differentiation)

CAR Expression Assay (Western Blot, mRNA Levels, etc.)

Toxicity Assay (Fluorescence or FACS)

In Vivo Assays

Available Assays

Safety Study: Teratoma Formation Assay**

Efficacy Study: Cell Accumulation at Tumor Site & Effect On Tumor**

Tumor Killing Assay (Tumor Size & Mouse Death Rate)

On/Off Target Testing

Persistence and Exhaustion

**More service details below (under Technical Details)

Don't see what you are looking for? Contact us to ask about your assay needs today.

Inquire & Learn More About Our iPSC Services



- Call: 1-866-497-4180
- Email: info@appliedstemcell.com


TARGATT™ HEK293 Master Cell Line For Site-Specific Knock-in

TARGATT™ iPSC-iNK Platform

- >40% gene integration efficiency
-Site-specific knock-in
- NK cells derived from an unlimited source of iPSCs
- Safe and efficient gene editing protocols

TARGATT™ iPSC-iNK Platform

TARGATT™ Antibody Screening Library Construction Service & Kits

GMP Grade iPSC Services & Products

- iPSC Generation
- iPSC Gene Editing
- iPSC Differentiation
- iPSC cGMP Control Lines

GMP Grade iPSC Services & Products




Products and Services
Technical Details

Animal Studies - Saftey and Efficacy

(CAR-iNK Line Generated By TARGATTTechnology)

1. CAR-iNK Saftey Study

Objective: Use a teratoma formation assay to assess the safety of CAR-iNK cells.

* Teratoma Formation Assay = A "gold standard" to test pluripotency.

Expected Results: Mice injected with CAR-iPSC would develop teratoma (with characteristics of all three germ layers). Mice injected with CAR-iNKs would not (suggesting a minimized risk for tumor formation).


2. CAR-iNK Efficacy Study (Xenograft Models)


1. Test iNK accumulation at the tumor site

2. Study the enhancement effects of CAR-iNK on tumors 

Expected Results:
1. CAR-iNKS would accumulate the tumor loci with greater efficiency compared to iNKS
2. CAR-iNKs would display an enhanced efficacy compared to iNKs

Experimental Designs & Timeline

1. Intervenous Injection of Daudi-Fluc cells (Day 0)
2. Intervenous Injection of iNK or CAR-iNK cells (Day 10)
3. Bioluminescence Imaging (Days: inquire)
4. Blood Collection (Day 29)
- measurement of cytokine levels; immunohistochemical staining for human CD56 in the spleen

* NOTE: For CAR-iNK & iNK Cells

- Cells are differentiated from CAR-iPSC or iPSC lines

- CAR-iNK and iNK cells are characterized by a standard panel of NK cell markers and an in vitro cytotoxicity assay (primary cells are used as a control)